FNDX vs XBI
Schwab Fundamental US Large Company Index ETF vs SPDR S&P Biotech ETF
- • FNDX has the lower expense ratio at 0.25% vs 0.35% for XBI.
- • FNDX pays a higher dividend yield (1.50%).
Side-by-side metrics
| Metric | FNDX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.50% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $25.91B | $8.30B |
YTD return | 12.17% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 1.09 |
P/E ratio | 20.94 | — |
Last price | $30.16 | $133.66 |
Inception | — | — |
Issuer | Schwab | State Street |
FNDX top holdings
| AAPL | Apple Inc | 4.18% |
| XOM | Exxon Mobil Corp | 2.54% |
| MSFT | Microsoft Corp | 2.28% |
| GOOGL | Alphabet Inc Class A | 2.28% |
| INTC | Intel Corp | 2.21% |
| AMZN | Amazon.com Inc | 1.88% |
| GOOG | Alphabet Inc Class C | 1.82% |
| CVX | Chevron Corp | 1.63% |
| JPM | JPMorgan Chase & Co | 1.49% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.47% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About FNDX
FNDX (Schwab Fundamental US Large Company Index ETF) is US large caps weighted by fundamental factors. Managed by Schwab, the fund carries $25.9B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.50%. Its largest holding is Apple Inc (AAPL), which represents 4.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.